menu
    • menu
    [{"orgOrder":0,"company":"Orphazyme","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Preclinical","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Orphazyme \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Saniona","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"SAN2355","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Preclinical","graph3":"Saniona","amount2":1.04,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Saniona \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Neumirna Therapeutics","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Series A Financing","leadProduct":"NMT.001","moa":"miR-134","graph1":"Neurology","graph2":"Preclinical","graph3":"Neumirna Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Neumirna Therapeutics \/ Angelini Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Neumirna Therapeutics \/ Angelini Ventures"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vesper Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Vesper Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"Retinoic acid receptor RXR (RXR)","graph1":"Neurology","graph2":"Preclinical","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IO Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Hoba Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Protein","year":"2023","type":"Series A Financing","leadProduct":"Recombinant Human Meteorin","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoba Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hoba Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Hoba Therapeutics \/ Indaco Venture Partners"},{"orgOrder":0,"company":"Glysious","sponsor":"Tetra Pharm Technologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Glysious","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glysious \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Glysious \/ Tetra Pharm Technologies"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Saniona

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Saniona

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAN2355

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,035.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jazz Enters Exclusive Licensing Agreement with Saniona to Develop & Commercialize SAN2355

                            Details : Under the licensing, Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications.

                            Product Name : SAN2355

                            Product Type : Miscellaneous

                            Upfront Cash : $42.5 million

                            August 20, 2025

                            Lead Product(s) : SAN2355

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,035.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neumirna Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Neumirna Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMT.001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Angelini Ventures

                            Deal Size : $20.9 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Angelini, Neumirna Lead €20M Series A for RNA Therapy in Neurological Disorders

                            Details : The proceeds from the financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : NMT.001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Angelini Ventures

                            Deal Size : $20.9 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IO Biotech

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            IO Biotech

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Io Therapeutics Presents IRX4204 Results for ALS Treatment

                            Details : IRX4204 is the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : IRX4204

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glysious

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Glysious

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPT0201

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Tetra Pharm Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tetra Pharm and Glysious Partner to Develop Transdermal Endocannabinoid System Drugs

                            Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : TPT0201

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Tetra Pharm Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vesper Bio

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Vesper Bio

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Vesper Bio Awarded Grant to Assess Sortilin Inhibitors for Parkinson's

                            Details : The funding aims to support the clinical advancement of Vesper's lead product VES001, a sortilin inhibitor. Currently, it is being evaluated in the preclinical trial studies for Parkinson's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : VES001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hoba Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Hoba Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Meteorin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Indaco Venture Partners

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Hoba Therapeutics Raises EUR 23 Million in a Series A to Advance New Drug Candidate Against Chronic Neuropathi...

                            Details : The net proceeds will be used to advance new drug candidate, HB-086, a non-opioid compound with a unique mode of action, targeting the underlying cause in the peripheral nervous system against chronic neuropathic pain.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 11, 2023

                            Lead Product(s) : Recombinant Human Meteorin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Indaco Venture Partners

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novo Nordisk

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novo Nordisk To Enter Phase 3 Development in Alzheimer’s Disease with Oral Semaglutide

                            Details : Novo Nordisk announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.

                            Product Name : Rybelsus

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 16, 2020

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Orphazyme

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Orphazyme

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arimoclomol Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson’s Disease Research

                            Details : Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).

                            Product Name : Miplyffa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 17, 2020

                            Lead Product(s) : Arimoclomol Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth